Stock-Based Compensation	6 Months Ended
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The Human Resources and Compensation Committee of our Board of Directors granted 27,711 deferred share units (“DSUs”) and 55,866 deferred RSUs (“DRSUs”) to our non-employee directors in the first six months of 2026 under our Omnibus Equity Incentive Plan. No equity grants were made to our employees in the first six months of 2026 under Omnibus Equity Incentive Plan. We measure the fair value of grants of DSUs and DRSUs based on the closing market price of a share of our common stock on the date of the grant (or if the market is not open for trading on such date, the immediately preceding day on which the market is open for trading). The weighted average fair value per share was $6.32 for DSUs and $8.95 for DRSUs granted to non-employee directors during the six months ended June 30, 2026. During the first six months of 2026, the Company issued an aggregate of 250,000 of common stock purchase warrants to a consultant pursuant to an agreement with respect to consulting services. The warrants were measured at their fair value on the grant date, resulting in stock-based compensation expense of $0.7 million, which was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations. In the three months ended June 30, 2026 and 2025, we recognized $1.4 million and $1.8 million, respectively, of stock-based compensation expense. The majority of the expense, $1.2 million and $1.6 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold. In the six months ended June 30, 2026 and 2025, we recognized $3.3 million and $2.4 million, respectively, of stock-based compensation expense. The majority of the expense, $2.9 million and $1.9 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold. As of June 30, 2026, the unrecognized compensation cost related to the unvested portion of all stock-based awards was approximately $4.1 million and is expected to be recognized over the remaining vesting period of the respective grants.

The Human Resources and Compensation Committee of our Board of Directors granted 27,711 deferred share units (“DSUs”) and 55,866 deferred RSUs (“DRSUs”) to our non-employee directors in the first six months of 2026 under our Omnibus Equity Incentive Plan. No equity grants were made to our employees in the first six months of 2026 under Omnibus Equity Incentive Plan.

We measure the fair value of grants of DSUs and DRSUs based on the closing market price of a share of our common stock on the date of the grant (or if the market is not open for trading on such date, the immediately preceding day on which the market is open for trading). The weighted average fair value per share was $6.32 for DSUs and $8.95 for DRSUs granted to non-employee directors during the six months ended June 30, 2026.

During the first six months of 2026, the Company issued an aggregate of 250,000 of common stock purchase warrants to a consultant pursuant to an agreement with respect to consulting services. The warrants were measured at their fair value on the grant date, resulting in stock-based compensation expense of $0.7 million, which was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations.

In the three months ended June 30, 2026 and 2025, we recognized $1.4 million and $1.8 million, respectively, of stock-based compensation expense. The majority of the expense, $1.2 million and $1.6 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold.

In the six months ended June 30, 2026 and 2025, we recognized $3.3 million and $2.4 million, respectively, of stock-based compensation expense. The majority of the expense, $2.9 million and $1.9 million, respectively, was recorded in selling and

administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold.

As of June 30, 2026, the unrecognized compensation cost related to the unvested portion of all stock-based awards was approximately $4.1 million and is expected to be recognized over the remaining vesting period of the respective grants.